Idexx Laboratories (IDXX)
Technical, fundamental, and sentiment analysis with recent related videos.
IDXX rates Bullish overall. The fundamental read is bullish: the company passes 7 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 20.57); revenue is growing about 8.5% per year; net income is growing about 16.3% per year. The technical picture is neutral: price is 2.8% below the 200-day moving average; 5.1% above the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bullish (composite 78/100), based on 6 news articles from recent coverage.
Revenue 3-year avg +8.5%. Net income 3-year avg +16.3%.
Price vs 20DMA +5.0%. RSI 61.92. Bollinger state: Inside Bands.
Composite score 78/100 from the AI judge, based on 6 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamentals are Bullish: revenue has averaged 8.5 percent per year and net income averaged 16.3 percent per year over three years, with no outlier flagged. Technical is Neutral: the Relative Strength Index (RSI), a momentum reading, sits at 61.9 and price is 5.0 percent above the 20-day moving average, but the stock remains below its 200-day average and volume is below its 20-day average, so momentum is constructive but not decisive. Sentiment is Bullish, composite 78/100. Combined, strong fundamentals plus bullish sentiment push the overall rating to Bullish despite a Neutral technical picture.
Recent news: Coverage is broadly positive: multiple items report an earnings beat, a raise to full-year 2026 revenue guidance and an expanded diagnostics and imaging test menu, while management expects Q3 revenue and EPS growth from CAG Diagnostics momentum, higher testing volumes and software gains. Jefferies reiterated a Buy and shares have rebounded recently, though Robeco's 38% stake cut and the stock's 16.73% year-to-date decline introduce some caution; GDELT's 62/100 tone modestly supports the bullish tilt.
Latest Videos
- No qualified videos yet.